All In Biotech

Drug Trial Radar · NCT07014488

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects

A Single-center, Single-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jun 20, 2025

Primary completion

Aug 1, 2025

Study completion Aug 1, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study was designed to evaluate the pharmacokinetic effects of Rifampicin on HRS-5041 after oral administration of HRS-5041 tablets in healthy subjects.

Conditions

  • Prostate Cancer

Interventions

  • HRS-5041 TabletsDrug

    HRS-5041 tablets.

  • Rifampicin CapsuleDrug

    Rifampicin capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve from time 0 to time t (AUC0-t)Time frame: 0 to anticipated 23 days.
  2. Area Under the Curve from time 0 to infinity (AUC0-∞)Time frame: 0 to anticipated 23 days.
  3. Maximum concentration (Cmax)Time frame: 0 to anticipated 23 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.